

ARTICLE

**Improved Detection of Decreased Glucose Handling Capacities via Novel  
Continuous Glucose Monitoring-Derived Indices: AC\_Mean and AC\_Var**

Hikaru Sugimoto,<sup>1</sup> Ken-ichi Hironaka,<sup>2</sup> Tomoaki Nakamura,<sup>3</sup> Tomoko Yamada,<sup>4</sup> Hiroshi  
Miura,<sup>5</sup> Natsu Otowa-Suematsu,<sup>4</sup> Masashi Fujii,<sup>2,6</sup> Yushi Hirota,<sup>4</sup> Kazuhiko Sakaguchi,<sup>4</sup>  
Wataru Ogawa,<sup>4\*</sup> and Shinya Kuroda<sup>1,2\*</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology, Graduate School of Medicine, The  
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

<sup>2</sup>Department of Biological Sciences, Graduate School of Science, The University of Tokyo,  
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

<sup>3</sup>Department of Diabetes and Endocrinology, Akashi Medical Center, 743-33 Okubo-cho  
Yagi, Akashi, Hyogo 674-0063, Japan

<sup>4</sup>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University  
Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan

<sup>5</sup>Department of Diabetes and Endocrinology, Takatsuki General Hospital, 1-3-13  
Kosobe-cho, Takatsuki, Osaka 569-1192, Japan

<sup>6</sup>Department of Mathematical and Life Sciences, Graduate School of Integrated Sciences for  
Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-hiroshima City, Hiroshima  
739-8526, Japan

\*Corresponding authors: Wataru Ogawa, [ogawa@med.kobe-u.ac.jp](mailto:ogawa@med.kobe-u.ac.jp); and Shinya Kuroda,

[skuroda@bs.s.u-tokyo.ac.jp](mailto:skuroda@bs.s.u-tokyo.ac.jp)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **ABSTRACT**

28 **Background**

29 Efficiently detecting impaired glucose control abilities is a pivotal challenge in public health.  
30 This study assessed the utility of relatively easy-to-measure continuous glucose monitoring  
31 (CGM)-derived indices in estimating glucose handling capacities calculated from  
32 resource-intensive clamp tests.

33

34 **Methods**

35 We conducted a prospective, single-center, observational cohort study of 64 individuals  
36 without prior diabetes diagnosis. The study utilized CGM, oral glucose tolerance test, and  
37 hyperglycemic and hyperinsulinemic-euglycemic clamp tests. We validated CGM-derived  
38 indices characteristics using an independent dataset and mathematical model with simulated  
39 data.

40

41 **Findings**

42 A novel CGM-derived index, AC\_Var, was significantly correlated with insulin sensitivity ( $r$   
43  $= -0.31$ ; 95% CI:  $-0.52$  to  $-0.06$ ), insulin clearance ( $r = -0.31$ ; 95% CI:  $-0.54$  to  $-0.06$ ), and  
44 disposition index (DI) ( $r = -0.31$ ; 95% CI:  $-0.52$  to  $-0.07$ ) calculated from clamp tests.

45 AC\_Var was also significantly correlated with insulin resistance ( $r = 0.48$ ; 95% CI:  $0.23$  to  
46  $0.68$ ) in an independent dataset. Multivariate analyses indicated AC\_Var's contribution to  
47 predicting reduced blood glucose control abilities independent from conventional  
48 CGM-derived indices. The prediction model's accuracy utilizing CGM-measured glucose  
49 standard deviation and AC\_Var as input variables, with clamp-derived DI as the outcome,  
50 closely matched that of predicting clamp- from OGTT-derived DI. Mathematical simulations  
51 also underscored AC\_Var's association with insulin clearance and DI.

52

53 **Interpretation**

54 CGM-derived indices, including AC\_Var, can be useful for screening decreased blood  
55 glucose control ability. We developed a web application that calculates these indices  
56 (<https://cgm-ac-mean-std.streamlit.app/>).

57

58 **Funding**

59 The Japan Society for the Promotion of Science KAKENHI, CREST, Japan Science and  
60 Technology Agency, and Uehara Memorial Foundation.

61 (250/250 words)

62

63 **Keywords**

64 Continuous glucose monitoring, oral glucose tolerance test, clamp test, disposition index,  
65 insulin clearance

66

## 67 INTRODUCTION

68 Pre-diabetes (pre-DM), a condition in which blood glucose controlling mechanisms are  
69 slightly disrupted, is a high-risk condition for the development of type 2 diabetes mellitus  
70 (T2DM) and its associated complications.<sup>1</sup> Approximately 5–10% of patients with pre-DM  
71 develop T2DM annually,<sup>1,2</sup> with up to 70% eventually developing T2DM.<sup>1,3</sup> Despite lower  
72 blood glucose levels in pre-DM compared to T2DM, individuals with pre-DM are at elevated  
73 risk of chronic kidney disease<sup>4</sup> and cardiovascular disease,<sup>5</sup> which are common complications  
74 of diabetes. However, preventive measures through pharmaceutical or lifestyle interventions  
75 can impede the progression to T2DM and mitigate complications.<sup>1,6,7</sup> Consequently, pre-DM  
76 screening followed by targeted interventions has demonstrated cost-effectiveness.<sup>8</sup>

77 Optimal methods for detecting the decreased ability to control blood glucose,  
78 however, have yet to be established. Hemoglobin A1c (HbA1c) and fasting blood glucose  
79 (FBG) have been recommended for screening for pre-DM, but they lack precision for  
80 prediabetes screening and even their combination has a diagnostic sensitivity of only about  
81 60%.<sup>9–11</sup> The 2-h oral glucose tolerance test (OGTT) has long been the gold standard  
82 diagnostic method for pre-DM and T2DM.<sup>12</sup> However, the cost, time, patient inconvenience,  
83 and lack of reproducibility of the OGTT make it impractical for patient care.<sup>12</sup> Moreover,  
84 these indices lack information on glycemic variability and changes in glucose levels  
85 throughout the day, which are relevant to T2DM complications.<sup>13,14</sup> Insulin sensitivity and  
86 insulin secretion impairment precede T2DM development, with insulin resistance emerging  
87 years prior and decreased  $\beta$ -cell function already present in pre-DM.<sup>1</sup> Although  
88 hyperinsulinemic-euglycemic and hyperglycemic clamp tests have been the gold standards  
89 for assessing insulin sensitivity and insulin secretion,<sup>15</sup> their resource intensiveness impedes  
90 practicality in screening. Consequently, the development of more accurate and accessible  
91 methods for detecting reduced glucose control abilities constitutes a pressing public health  
92 challenge.

93 Continuous glucose monitoring (CGM) has emerged as a promising avenue for  
94 identifying individuals with reduced glucose handling capacity.<sup>16–18</sup> CGM-derived indices  
95 identify individuals who are not identified as pre-DM by FBG, HbA1c, or OGTT, but who  
96 have high levels of postprandial glucose, a characteristic of pre-DM and even T2DM.<sup>19</sup> A  
97 CGM-derived index has demonstrated the ability to identify individuals with a high risk of  
98 progressing to T2DM.<sup>20</sup> Some CGM-derived indices also correlate with insulin secretion,  
99 insulin sensitivity, or the disposition index (DI).<sup>19,21–24</sup> While various glycemic variability  
100 indices derived from CGM have been reported, their relationship to glucose handling  
101 capacity and their potential for identifying individuals with reduced glucose handling,  
102 particularly in a population predominantly composed of healthy individuals, remain unclear.

103 Here, we assessed previously established CGM-derived indices<sup>19,25</sup> and introduced  
104 two novel indices (AC\_Mean and AC\_Var) based on autocorrelation function of glucose  
105 levels. By examining the correlation between these indices and indices calculated from  
106 OGTT or clamp tests, we found that AC\_Mean and AC\_Var were significantly correlated  
107 with insulin clearance or the DI, unlike the other CGM-derived indices. In addition,  
108 multivariate analyses indicated that CGM-derived indices, including AC\_Mean and AC\_Var,  
109 contributed to the prediction of decreased blood glucose control abilities. A mathematical  
110 model with simulated data also indicated that AC\_Mean and AC\_Var were associated with  
111 insulin clearance and the DI.

112

## 113 **METHODS**

### 114 **Subjects and measurements**

115 This study was conducted in accordance with the Declaration of Helsinki and its amendments,  
116 and was approved by the ethics committee of Kobe University Hospital (Approval No. 1834;  
117 Kobe, Japan). Written informed consent was obtained from all subjects. Study participants  
118 who had no previous diagnosis of diabetes and were over 20 years old were recruited from

119 Kobe University Hospital (Hyogo, Japan) from January 2016 to March 2018. Exclusion  
120 criteria were: 1) taking medications that affect glucose metabolism (e.g., steroids,  $\beta$  blockers);  
121 2) patients with psychiatric disorders; 3) pregnant or breast-feeding women; and 4) deemed  
122 unfit for any other reason by attending physicians.

123 The study participants initially underwent a 75-g OGTT in the morning after an  
124 overnight fast. Following the OGTT, they wore a CGM device (iPro; Medtronic, Minneapolis,  
125 MN, USA) for more than 72 h. Within 7 days after the OGTT, the participants underwent a  
126 consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp test. Detailed procedures  
127 for the OGTT, consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp, and  
128 CGM can be found in Supplementary Text 1.

129 A total of 70 participants were initially enrolled. One participant taking a  $\beta$  blocker,  
130 two participants with missing CGM data, two participants with protocol deviation, and one  
131 participant with missing OGTT and/or clamp data were excluded from the analysis.  
132 Consequently, data from 64 participants were used in the analysis (Fig. S1). The sample size  
133 of 64 participants closely aligned with the cohort of 57 individuals investigated in a previous  
134 study, where statistically significant correlations between CGM-derived indices and the  
135 ability to regulate blood glucose were demonstrated.<sup>19</sup> Of note, with a type I error of 0.05, a  
136 power of 0.8, and an expected Spearman correlation coefficient of 0.35, a sample size of 66  
137 (Bonett and Wright's method) or 64 (Caruso and Cliff's method) was required to detect a  
138 significant difference from zero in the correlation coefficient. This sample size estimation  
139 was performed using SPSS version 29 (SPSS Inc.).

140

#### 141 **Subjects and measurements of a previously reported dataset**

142 We also performed an analysis using publicly available data sets of CGM (Dexcom G4  
143 CGM System; Dexcom, Fort Lauderdale, FL, USA), OGTT, and steady state plasma glucose  
144 (SSPG) test outcomes from a previously reported study.<sup>19</sup> The participants of that study,

145 recruited from the San Francisco Bay Area, had no previous diagnosis of diabetes.<sup>19</sup> Among  
146 the study subjects (32 females and 25 males), 5, 14, and 38 individuals met their criteria of  
147 “type 2 diabetes” (HbA1c  $\geq$  6.5%, FBG  $\geq$  126 mg/dL, or 2-h glucose during 75-g OGTT  $\geq$   
148 200 mg/d), “pre-diabetes” (HbA1c  $>$  5.7% and  $<$  6.5%, FBG 100–125 mg/dL, or 2-h glucose  
149 during 75-g OGTT 140–199 mg/dL) and “normoglycemia” (glucose-related parameters  
150 below the diagnostic thresholds for pre-diabetes).<sup>19</sup>

151

### 152 **CGM-derived parameters**

153 CGM\_Mean and CGM\_Std represent the mean and standard deviation of glucose values  
154 measured by CGM, respectively. CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE,  
155 ADRR, MVALUE, and MAG were calculated using EasyGV software.<sup>25</sup> Here, we  
156 introduced novel indices, the mean (AC\_Mean) and the variance (AC\_Var) of the  
157 autocorrelation function of glucose values at lags 1–30 with a lag of 5 min. While  
158 autocorrelation function has been used to analyze this type of time series data,<sup>26,27</sup> it has not  
159 been thoroughly investigated to date. AC\_Mean and AC\_Var used in analyzing blood  
160 glucose levels after consuming standardized meals<sup>19</sup> were calculated from the autocorrelation  
161 function at lags 1–10, as we had CGM data available for only 2.5 h after standardized meals  
162 were consumed.

163 DTW\_Low, DTW\_Mod, and DTW\_Sev are previously proposed CGM-derived  
164 indices that represent the dysregulation of glycemia.<sup>19</sup> These indices were calculated by a  
165 previously reported method.<sup>19</sup> In brief, the time series data of CGM were fragmented into  
166 sliding windows of 2.5 h, with a 75% overlap. Then, by applying spectral clustering, three  
167 clusters of glucose patterns (low, moderate, and severe) were identified, and the fraction of  
168 time in each category was defined as DTW\_Low, DTW\_Mod, and DTW\_Sev, respectively.

169

### 170 **Calculation of clinical indices**

171 Insulinogenic index (I.I):

172 Ratio of the increment of immunoreactive insulin (IRI) to that of plasma glucose at 30 min  
173 after the onset of the OGTT.

174 Composite index:

175 
$$[10000/\sqrt{\text{FPG} \times \text{FIRI} \times \text{G} \times \text{I}}],$$

176 where FPG, FIRI, G, and I are fasting plasma glucose, fasting IRI, mean blood glucose levels,  
177 and mean serum IRI concentrations during the OGTT, respectively.

178 Oral DI:

179 Product of the composite index and the ratio of the area under the insulin concentration curve  
180 from 0 to 120 min to that for plasma glucose from 0 to 120 min, without using the data  
181 measured at 90 min, in the OGTT.

182 AUC\_IRI:

183 Incremental area under the IRI concentration curve from 0 to 10 min during the  
184 hyperglycemic clamp.

185 Insulin sensitivity index (ISI):

186 The mean glucose infusion rate during the final 30 min of the clamp (mg/kg/min) divided by  
187 both the plasma glucose (mg/dL) and serum insulin ( $\mu\text{U/mL}$ ) levels at the end of the clamp  
188 and then multiplying the resulting value by 100.

189 Clamp DI:

190 The product of AUC\_IRI and ISI.

191 Metabolic clearance rate of inulin (MCRI):

192 Ratio of insulin infusion rate to the steady-state plasma insulin concentration during the  
193 hyperinsulinemic-euglycemic clamp test.

194

195 **Mathematical model estimating insulin sensitivity, secretion, and clearance**



196 To estimate insulin sensitivity, insulin secretion, and insulin clearance from clamp tests, we  
197 constructed a mathematical model of the feedback loop that links glucose and insulin as  
198 shown in a previous study<sup>28</sup> as follows:

$$199 \quad \frac{dG}{dt} = \text{flux 1} - \text{flux 2} + \text{flux 3} - \text{flux 4} + \text{influx } G = k_1 Y - k_2 G + \frac{k_3}{k_8 + I} - k_4 GI + f_1(t)$$

$$200 \quad \frac{dI}{dt} = \text{flux 6} - \text{flux 7} + \text{influx } I = k_6 X - k_7 I + f_2(t)$$

$$201 \quad \frac{dY}{dt} = -\text{flux 1} + \text{flux 2} = -k_1 Y + k_2 G$$

$$202 \quad \frac{dX}{dt} = \text{flux 5} - \text{flux 6} = k_5 Y - k_6 X,$$

203 where the variables  $G$  and  $I$  denote blood glucose and insulin concentrations, respectively.  
204 The fluxes, influx  $G$  and influx  $I$  denote glucose and insulin infusions, respectively. These  
205 fluxes were estimated using a previously reported method.

206 For each of the 64 subjects, the parameters of the model to reproduce the time course  
207 were estimated by a meta-evolutionary programming method to search the minimum globally,  
208 followed by application of the nonlinear least squares technique to search the minimum  
209 locally, as previously described.<sup>29</sup> Each parameter of the model for serum glucose and insulin  
210 concentration was estimated in the range from  $10^{-4}$  to  $10^4$ . For these methods, the parameters  
211 were estimated to minimize the objective function value, which is defined as residual sum of  
212 the square (RSS) between the actual time course obtained by clamp analyses and the model  
213 trajectories. RSS used in the model for serum glucose and insulin concentration was given by  
214 the following equation:

$$215 \quad \text{RSS} = \frac{n_I}{n_G + n_I} \sum_{i=1}^{n_G} [G(t_i) - G_{\text{sim}}(t_i)]^2 + \frac{n_G}{n_G + n_I} \sum_{i=1}^{n_I} [I(t_i) - I_{\text{sim}}(t_i)]^2,$$

216 where  $n_G$  and  $n_I$  are the total numbers of time points of measuring blood glucose and  
217 insulin, respectively, and  $t_i$  is the time of  $i$ -th time point.  $G(t)$  is the time-averaged blood  
218 glucose concentration within the time range  $(t - 5)$  min to  $t$  min with every 1-min interval,  
219  $I(t)$  is the blood insulin concentration at  $t$  min.  $G_{\text{sim}}(t)$  and  $I_{\text{sim}}(t)$  are simulated blood

220 glucose and insulin concentrations, respectively. Blood glucose and insulin concentrations of  
221 each subject were normalized by dividing them by the respective maximum value. The  
222 numbers of parents and generations in the meta-evolutionary programming were 400 and  
223 4000, respectively.

#### 224 **Mathematical model used for simulating the characteristics of AC\_Mean and AC\_Var**

225 In simulating the characteristics of AC\_Mean and AC\_Var, we used a simple and stable  
226 model,<sup>30</sup> which can be written as follows:

$$227 \quad \frac{dG}{dt} = -k_{\text{glu}}G - k_{\text{sen}}IG + k_{\text{pro}} + f$$
$$228 \quad \frac{dI}{dt} = \frac{k_{\text{sec}}}{k_{\text{tim}}} \int_{t-k_{\text{tim}}}^t G ds - k_{\text{cle}}I$$

229 where the variables  $G$  and  $I$  denote blood glucose and insulin concentrations, respectively.

230 Parameter values reported as the averages for healthy subjects were as follows:<sup>30</sup>

$$231 \quad k_{\text{glu}} = 0.0226, k_{\text{sen}} = 5.64 \times 10^{-5}, k_{\text{pro}} = 1.93,$$
$$232 \quad k_{\text{sec}} = 0.074, k_{\text{tim}} = 14.9, k_{\text{cle}} = 0.1262.$$

233 We simulated how 24-h profiles of  $G$  changed as  $k_{\text{sec}}k_{\text{sen}}$  and  $k_{\text{cle}}$ , which correspond to  
234 the DI and insulin clearance, respectively, were changed from one-half to twice as large as  
235 the values. Five mg/dL/min glucose was applied for 10 min at 6-, 12-, and 18-h as the  
236 external input of glucose  $f$ . We also calculated the AC\_Mean and AC\_Var from  $G$  added  
237 with zero-mean gaussian white noise with variances of 0.25, 0.5, or 1.

238

#### 239 **Prediction models and statistical analyses**

240 In this study, we investigated the predictive performance of CGM-derived indices for  
241 assessing the decline in blood glucose control ability across five main methodologies:  
242 multiple linear regression, partial least squares (PLS) regression, least absolute shrinkage  
243 operator (LASSO) regression, random forests, and logistic regression. Of note, these  
244 prediction models were conducted as post hoc analyses. The input variables for these models

245 consisted of 27 variables: body mass index (BMI), abdomen circumference (ACir), body fat  
246 percentage, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol  
247 (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), high-density  
248 lipoprotein cholesterol (HDL-C), FBG, HbA1c, CGM\_Mean, CGM\_Std, CONGA, LI,  
249 JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG, DTW\_Mod,  
250 DTW\_Sev, AC\_Mean, and AC\_Var. This modeling was conducted using scikit-learn, a  
251 python-based tool kit.

252 The predictive performance assessment of multiple linear regression included  
253 measures such as the coefficient of determination ( $R^2$ ), the adjusted coefficient of  
254 determination ( $Adj R^2$ ), and Akaike information criterion (AIC). The multicollinearity of the  
255 input variables was estimated by the variance inflation factor (VIF). PLS regression was  
256 conducted to estimate the importance of the input variables in predicting the DI. The variable  
257 importance in projection (VIP) scores,<sup>31</sup> which were generated from PLS regression, were  
258 used for estimating the importance of the input variables. Lasso regression is a kind of linear  
259 regression with L1 regularization.<sup>32,33</sup> The optimal regularization coefficients, lambda, were  
260 based on leave-one-out cross validation. For multiple linear regression, PLS regression,  
261 LASSO regression, and logistic regression, z-score normalization was performed on each  
262 input variable.

263 Random forest is an ensemble learning method, which generates classification  
264 decision trees by selecting subsets of input predictor variables randomly.<sup>34</sup> The study  
265 employed 300 decision trees with Gini as the criterion for determining the best splits. The  
266 predictive performance of random forests was assessed using accuracy and F1 score based on  
267 leave-one-out cross-validation. The importance of the input variables in predicting glycemic  
268 anomaly is based on the permutation and the feature importance function of the random forest  
269 function. Boruta<sup>35</sup> was also used to test whether the input variables is usable for the  
270 prediction.

271 Associations between indices were assessed using Spearman's correlation test, and  
272 correlation coefficients were reported with 95% confidence intervals (Cis) through bootstrap  
273 resampling. The number of resamples performed to form the bootstrap distribution was set at  
274 10000.  $P < 0.05$  was considered statistically significant. Benjamini-Hochberg's multiple  
275 comparison test was also performed with a significance threshold of  $Q < 0.05$ .

276 Hierarchical clustering analysis was also conducted using a method that combines  
277 Euclidean distance measure and Ward linkage. It was adopted after Z score normalization.  
278 Comparisons among individuals in each cluster were performed by analysis of variance  
279 followed by Tukey's honestly significant difference test.

280

## 281 **RESULTS**

### 282 **Autocorrelation of glucose levels fluctuations**

283 In this study, our primary objective was to devise novel CGM-derived metrics that represent  
284 the glucose handling capacity of the living body. To achieve this, we conducted CGM, an  
285 OGTT, and a consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp test in  
286 individuals without prior diabetes diagnosis, enabling us to focus on early indicators of  
287 reduced blood glucose control abilities.

288 We focused on the autocorrelation of glycemic fluctuation pattern, in particular, the  
289 mean (AC\_Mean) and the variance (AC\_Var) of the autocorrelation function at lags 1–30  
290 with the length of the lag for 5 min, given that glucose levels were measured every 5 min  
291 with the CGM device (Figs. 1 and S2). Figure 1 shows the autocorrelation function of  
292 glycemic fluctuation pattern in two representative subjects (Subjects #13 and #46), both of  
293 whom were categorized as normal glucose tolerance (NGT), but had different clamp DI  
294 values: 65.7 for Subject #13 and 11.5 for Subject #46.

295 For individuals with slower fluctuations in blood glucose levels, such as Subject #13,  
296 the autocorrelation function displayed a slower rate of decrease with increasing lag (AC\_

297 Mean: 0.62, AC\_Var: 0.049). By contrast, subjects with more rapid glucose fluctuations, such  
298 as Subject #46, exhibited a relatively swift decrease in autocorrelation function as the lag  
299 increased (AC\_Mean: 0.24, AC\_Var: 0.12). It is noteworthy that although Subject #46 had a  
300 lower clamp DI than Subject #13, the mean (CGM\_Mean) and standard deviation  
301 (CGM\_Std) of glucose values were also lower in Subject #46 (CGM\_Mean: 95; CGM\_Std:  
302 16) than in Subject #13 (CGM\_Mean: 107; CGM\_Std: 18). Moreover, given the definition  
303 formula for the autocorrelation function, the autocorrelation function would not change if  
304 calculated from blood glucose levels standardized to a mean of 0 and a variance of 1,  
305 indicating a possibility that AC\_Mean and AC\_Var can possess characteristics that differ  
306 from the average or the variability of glucose levels.

307         Given these findings, we hypothesized that these indices might possess some  
308 information about underlying glucose regulatory abilities that are not discernible through  
309 conventional measures such as OGTT or the mean and standard deviation of blood glucose  
310 levels. Consequently, our primary research objective was to ascertain the association between  
311 AC\_Mean and AC\_Var and glucose handling capacities, such as the DI and insulin clearance.  
312 Of note, the DI and insulin clearance reportedly reflect glucose dysregulation well and predict  
313 the development of future T2DM beyond FBG and the plasma glucose concentration at 120  
314 min during the OGTT (PG120).<sup>36,37</sup>

315

### 316 **Relationship between indices from CGM and those from OGTT or clamp tests**

317 We compared AC\_Mean and AC\_Var with indices obtained from OGTT or clamp tests to  
318 thoroughly assess the potential of these indices in estimating a decline in blood glucose  
319 control ability (Figs. 2A and S3). In this study, CGM, OGTT, and clamp tests were  
320 performed on 52 NGT, 9 impaired glucose tolerance (IGT), and 3 T2DM individuals (Table  
321 S1). PG120, I.I., composite index, and oral DI were calculated from the OGTT. AUC\_IRI,  
322 ISI, and clamp DI were calculated from clamp tests. Additionally,  $k_4$ ,  $k_5$ , and  $k_7$  were

323 calculated using a previously established mathematical model.<sup>29</sup> PG120 is the plasma glucose  
324 concentration at 120 min during OGTT. I.I., AUC\_IRI, and  $k_5$  correspond to insulin  
325 secretion. Composite index, ISI, and  $k_4$  correspond to insulin sensitivity.  $k_7$  corresponds to  
326 insulin clearance. DI is the product of insulin sensitivity and insulin secretion. Of note, we  
327 refrained from employing multiple testing corrections encompassing all pairwise  
328 comparisons in Figure 2A due to the interdependent nature of the conducted tests; we  
329 analyzed various indicators that represent the same abilities, aiming to confirm the  
330 meaningful correlations observed.

331 AC\_Mean exhibited a statistically significant correlation with  $k_7$  ( $r = 0.28$ ; 95% CI:  
332 0.04 to 0.50). AC\_Var displayed statistically significant correlations with the oral DI ( $r =$   
333  $0.28$ ; 95% CI:  $-0.51$  to  $-0.02$ ), clamp DI ( $r = -0.31$ ; 95% CI:  $-0.52$  to  $-0.07$ ),  $k_4$  ( $r = -0.31$ ;  
334 95% CI:  $-0.52$  to  $-0.06$ ), and  $k_7$  ( $r = -0.31$ ; 95% CI:  $-0.54$  to  $-0.06$ ). Since we were testing  
335 two indices, AC\_Mean and AC\_Var, we also applied the Benjamini-Hochberg's multiple  
336 comparison test for each comparison, resulting in  $Q < 0.05$  for these comparisons, validating  
337 the significance of the identified relationships among these indices. To further validate the  
338 relationships among these indices, we also investigated the relationships among AC\_Mean,  
339 AC\_Var,  $k_4k_5$  (corresponding to the clamp DI) and MCRI (corresponding to insulin  
340 clearance). AC\_Mean exhibited a statistically significant correlation with  $k_4k_5$  ( $r = 0.29$ ;  
341 95% CI: 0.05 to 0.50). AC\_Var displayed statistically significant correlations with  $k_4k_5$  ( $r =$   
342  $-0.29$ ; 95% CI:  $-0.50$  to  $-0.05$ ) and MCRI ( $r = -0.33$ ; 95% CI:  $-0.55$  to  $-0.08$ ). Additionally,  
343 AC\_Mean and AC\_Var calculated from different lags were also significantly correlated with  
344  $k_7$ , oral DI, and clamp DI (Fig. S4). Collectively, we conclude that AC\_Mean and AC\_Var  
345 are associated with the DI or insulin clearance.

346 For comparison, we also assessed commonly used indicators such as FBG and  
347 HbA1c, which have been recommended for pre-DM screening.<sup>9-11</sup> Moreover, we examined  
348 CGM-derived basic features such as mean (CGM\_Mean) and standard deviation (CGM\_Std)

349 as well as CGM-derived indices, DTW\_Low, DTW\_Mod, and DTW\_Sev. These indices  
350 have been shown to identify populations with decreased ability to control blood glucose  
351 within populations primarily composed of individuals categorized as having NGT.<sup>19</sup>  
352 DTW\_Low, DTW\_Mod, and DTW\_Sev were calculated using a previously reported  
353 method:<sup>19</sup> low DTW\_Low and high DTW\_Sev indicate high glucose concentration and  
354 variability and glucose dysregulation.

355 The indices that exhibited significant correlations with AC\_Mean or AC\_Var  
356 differed from those significantly correlated with FBG, HbA1c, or other indices derived from  
357 CGM data; the other indices were not significantly correlated with all of the oral DI, clamp  
358 DI,  $k_4$ , and  $k_7$ . By contrast, FBG, HbA1c, or the other CGM-derived indices were  
359 significantly correlated with PG120, I.I., and the composite index, where AC\_Mean and  
360 AC\_Var exhibited no significant correlations.

361

### 362 **Estimation of the decreased ability to control blood glucose by combining CGM-derived** 363 **indices**

364 Based on these findings, we hypothesized that a more accurate identification of individuals  
365 with disrupted glucose regulation could be achieved by combining AC\_Mean and AC\_Var  
366 with conventional indices. To test this hypothesis, we investigated the relationship among  
367 AC\_Var, DTW\_Sev, diabetes diagnosis, and clamp DI – an indicator of glycemic disability  
368 and a predictor of T2DM<sup>38</sup> (Fig. 2B). Due to a significant correlation between AC\_Mean and  
369 AC\_Var ( $r = -0.74$ ; 95% CI:  $-0.85$  to  $-0.60$ ) (Fig. S3), we focused on AC\_Var. AC\_Var was  
370 not significantly correlated with DTW\_Sev ( $r = 0.06$ ; 95% CI:  $-0.20$  to  $0.32$ ). In subjects  
371 with T2DM, both AC\_Var and DTW\_Sev were relatively high. Some subjects with high  
372 values of AC\_Var and DTW\_Sev were diagnosed with NGT or IGT, but their clamp DI was  
373 relatively low (Fig. 2B, \*1). Some subjects had low DTW\_Sev and low clamp DI (Fig. 2B,  
374 \*2), and others had low AC\_Var and low clamp DI (Fig. 2B, \*3). In these subjects, either

375 AC\_Var or DTW\_Sev was relatively high, suggesting a potential for combined use to  
376 enhance accuracy in identifying individuals with impaired glucose control.

377 Theoretically, dynamic time warping, an algorithm that is employed to calculate  
378 DTW\_Sev, aligns time series data globally and may not fully account for autocorrelated  
379 structure information.<sup>39</sup> Consequently, DTW\_Sev is mainly affected by the mean and the  
380 variance of glucose levels.<sup>40,41</sup> On the other hand, AC\_Var is calculated from autocorrelation  
381 of glucose levels and autocorrelation is not affected by the mean and the variance of levels  
382 given its definition formula. Collectively, these rationales also indicate that DTW\_Sev and  
383 AC\_Var can have different aspects of glucose characteristics and that a combination of these  
384 two indices may be useful in estimating glucose handling capacities.

385 To further explore the efficacy of this combination, we conducted clustering analysis  
386 based on these indices (Fig. 2C). The sum of DTW\_Low, DTW\_Mod, and DTW\_Sev was 1,  
387 DTW\_Low was excluded from this analysis. We divided the subjects into four groups based  
388 on the relatedness of the indices: cluster \$1 mainly contained subjects with low DTW\_Sev  
389 and low AC\_Var, cluster \$2 mainly contained subjects with low DTW\_Sev and relatively  
390 high AC\_Var, cluster \$3 mainly contained subjects with relatively high DTW\_Sev and low  
391 AC\_Var, and cluster \$4 mainly contained subjects with relatively high DTW\_Sev and  
392 relatively high AC\_Var. Subjects in cluster \$3 had statistically significantly lower oral DI  
393 than those in cluster \$1 (Fig. 2D), and subjects in cluster \$2 had statistically significantly  
394 lower clamp DI than those in cluster \$1, suggesting that subjects with high DTW\_Sev  
395 (cluster \$3) or high AC\_Var (cluster \$2) have glycemic disabilities. As expected, subjects in  
396 cluster \$4 had statistically significantly lower oral DI and clamp DI than those in cluster \$1  
397 (Fig. 2D).

398 We also conducted multiple regression analyses among oral DI, clamp DI, and the  
399 CGM-derived indices (Table 1).  $R^2$  of the models that predicted oral DI and clamp DI from  
400 DTW\_Mod, DTW\_Sev, and AC\_Var were 0.24 and 0.14, respectively. AC\_Var had an



401 independent negative correlation with oral DI and clamp DI that was statistically significant  
402 ( $P = 0.029$  and  $P = 0.010$ , respectively), suggesting that AC\_Var contributes to the prediction  
403 of DI independently of DTW\_Mod and DTW\_Sev. AC\_Var also had a negative correlation  
404 with clamp DI that was statistically significant ( $P = 0.048$ ) independently of CGM\_Std  
405 (Table 1C), which was also significantly correlated with clamp DI (Fig. 2A).  $R^2$ , the  
406 adjusted coefficient of determination (Adj  $R^2$ ), and the AIC of the model that predicted clamp  
407 DI from CGM\_Std and AC\_Var were 0.18, 0.15, and 583, respectively. Of note,  $R^2$ , Adj  $R^2$ ,  
408 and AIC of the model that predicted clamp DI from oral DI were only 0.15, 0.14, and 583,  
409 respectively. Collectively, we conclude that combining AC\_Var with conventional  
410 CGM-derived indices can increase the accuracy of predicting a decreased ability to control  
411 blood glucose.

412

### 413 **Predicting DI from CGM, single-point blood tests, and physical measurement-derived** 414 **indices**

415 To predict DI, which reflects glycemic disability and has been suggested as a predictor of the  
416 development of T2DM,<sup>37</sup> we conducted multiple linear regression analyses. Since the  
417 purpose of this study was to estimate glucose intolerance from relatively easy-to-measure  
418 indices, we included only CGM-derived indices, indices from a single blood test, and those  
419 from physical measurements as the input variables, as follows: CGM\_Mean, CGM\_Std,  
420 CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG,  
421 DTW\_Mod, DTW\_Sev, AC\_Mean, AC\_Var, TC, TGs, LDL-C, HDL-C, FBG, HbA1c, BMI,  
422 ACir, body fat percentage, SBP, and DBP.

423 To assess the multicollinearity of the input variables, we investigated the VIF of  
424 these variables (Fig. 3A). We removed the variable with the highest VIF one by one until the  
425 VIF of all variables were less than 10 (Fig. 3B), resulting in 18 variables (DBP, SBP,  
426 AC\_Var, AC\_Mean, HBGI, MAG, GRADE, DTW\_Mod, ACir, BMI, MODD, FBG, HbA1c,

427 TG, HDL-C, LDL-C, body fat percentage, MVALUE). AC\_Mean and AC\_Var were  
428 included in these 18 variables, suggesting their relatively low multicollinearity with other  
429 indices.  $R^2$  of the models that predicted oral DI and clamp DI from the 18 variables were  
430 0.64 and 0.50, respectively (Fig. S5A, B). Adj  $R^2$  and AIC of the models that predicted oral  
431 DI (Fig. S5A) and clamp DI (Fig. S5B) using both CGM-derived indices and indices from a  
432 single-point blood test or physical measurements were better than those of models that used  
433 only CGM-derived indices (Figs. S6A, B) or a single-point blood test and physical  
434 measurement-derived indices (Fig. S6C, D), indicating that CGM-derived indices in addition  
435 to non-CGM indices contribute to a more accurate DI prediction.

436 To avoid overfitting and to investigate the importance of the input variables in  
437 predicting DI, we also applied machine learning models, including PLS regression with VIP  
438 scores<sup>31</sup> (Fig. 3C, D) and least absolute shrinkage and selection operator (Lasso) regression<sup>33</sup>  
439 (Fig. S7). These regression models have been used for studies where the number of input  
440 variables are large relative to the sample size.<sup>42,43</sup> PLS regression has been used for datasets  
441 with mutually correlated input variables and output variable, and important predictors can be  
442 estimated by VIP.<sup>31</sup> Here, high VIP indicates high contribution of the variables in predicting  
443 DI. Lasso employs L1 regularization, which leads to models with fewer parameters, and has  
444 been used to select useful features to predict DM from numerous input variables.<sup>32</sup>

445 The cross validation indicated that the optimal number of PLS components was 2. At  
446 the component, the VIP of some CGM-derived indices, including AC\_Var, was higher than 1  
447 (Fig. 3D). The leave-one-out cross validation indicated that the optimal regularization  
448 coefficients of lasso (Lambda) were 0.061 for oral DI and 3.49 for clamp DI (Fig. S7A, B).  
449 At these Lambdas, the coefficients of AC\_Var were estimated as non-zero coefficients for  
450 both oral DI and clamp DI (Fig. S7C–F). Collectively, these results indicate that  
451 CGM-derived indices, including AC\_Var, contribute to the prediction of DI.

452 We also investigated the characteristics of AC\_Mean and AC\_Var in predicting the  
453 decreased ability to control blood glucose by conducting random forests and a logistic  
454 regression analysis with L1 regularization (Supplementary text 2, Figs. S8–10), suggesting  
455 that including AC\_Mean or AC\_Var alongside conventional indices enhances the accuracy of  
456 predicting decreased glucose control abilities.

457

#### 458 **Relationship among clinical parameters**

459 To provide an overview of the relationship among indices derived from OGTT, clamp tests,  
460 CGM, and other clinical parameters from a single blood test or physical measurements, we  
461 constructed a correlation network (Fig. 4). Correlation networks have been used to elucidate  
462 the interdependency and interconnectivity among different biomarkers of complex metabolic  
463 disorders such as T2DM.<sup>44</sup> In this network, AC\_Mean and AC\_Var were correlated with  
464 some insulin-related indices (blue nodes), but the correlations with other indices (red,  
465 magenta, and green nodes) were relatively small. We also applied the Benjamini-Hochberg's  
466 multiple comparison test for each comparison, and showed relationships with  $Q < 0.05$  in  
467 Table S2. AC\_Var was significantly correlated with  $k_7$ , oral DI, and clamp DI (Table S2).  
468 Collectively, we conclude that the autocorrelation function of glucose levels has the ability to  
469 capture a diminished capacity for blood glucose control that remains undetected by  
470 conventional indices.

471

#### 472 **Validation of the contributions of AC\_Mean and AC\_Var in predicting a decreased** 473 **ability to control blood glucose using an independent dataset**

474 To further validate the significance of AC\_Mean and AC\_Var in predicting reduced blood  
475 glucose control capacity, we conducted multivariate analyses (Fig. 5A–D) and constructed a  
476 correlation network (Fig. 5E) by using a different dataset.<sup>19</sup> This dataset included 57

477 participants who were free from prior diabetes diagnosis, with 5 individuals meeting the  
478 criteria for T2DM, 14 having pre-DM, and the remaining participants having NGT.

479 The assessment of multicollinearity using VIF revealed that AC\_Mean exhibited  
480 relatively low multicollinearity with other indices (Fig. 5A, B), consistent with findings from  
481 previous analyses (Fig. 3A, B). The VIF of the indices calculated using the previously  
482 reported dataset (VIFp) and those calculated using the dataset obtained in this study (VIFt)  
483 were statistically significantly correlated (Fig. 5C), indicating the validity of the relationship  
484 among the clinical parameters. The cross validation indicated that the optimal number of  
485 components of the PLS regression model predicting SSPG, which indicates insulin sensitivity,  
486 was 2. At the component, VIP of AC\_Var in predicting SSPG was higher than 1 (Fig. 5D),  
487 indicating that AC\_Var contribute to the prediction of SSPG. To avoid overfitting and to  
488 investigate the contributions of the input variables in estimating SSPG, we also conducted  
489 Lasso (Fig. S11). The leave-one-out cross validation showed that the optimal regularization  
490 coefficient, Lambda, was 0.69 (Fig. S11A, B). At the Lambda, the coefficients of AC\_Mean  
491 and AC\_Var were estimated as non-zero coefficients (Fig. S11C), suggesting that AC\_Mean  
492 and AC\_Var contribute to the prediction of SSPG.

493 A correlation network showed that AC\_Mean and AC\_Var were significantly  
494 correlated with SSPG ( $r = -0.36$ ; 95% CI:  $-0.57$  to  $-0.09$  and  $r = 0.48$ ; 95% CI:  $0.23$  to  $0.68$ ,  
495 respectively), but the correlations with other CGM-derived indices were relatively modest  
496 (Fig. 5E). We also applied the Benjamini-Hochberg's multiple comparison test for each  
497 comparison, and showed relationships with  $Q < 0.05$  in Table S3. Both AC\_Mean and  
498 AC\_Var were significantly correlated with SSPG (Table S3). These results were consistent  
499 with the result that AC\_Var was significantly correlated with  $k_4$ , which corresponds to  
500 insulin sensitivity (Fig. 2A). These results confirm that the characteristics of AC\_Mean and  
501 AC\_Var are reproducible in capturing reduced blood glucose control ability.

502 To investigate the effects of meals on AC\_Mean and AC\_Var, we calculated the  
503 indices using the previously reported CGM data that were collected after consuming  
504 standardized meals<sup>19</sup> (Fig. S12). The standardized meals were about the same in calories, but  
505 differed in the amounts of proteins, fat, and fiber: cornflakes and milk (Cereal) were low in  
506 fiber and high in sugar, peanut butter sandwiches (Bread and PB) were high in fat and high in  
507 protein, and PROBAR protein bars (Bar) were moderate in fat and protein, as previously  
508 described.<sup>19</sup> The previously reported indices, DTW\_Low, DTW\_Mod, and DTW\_Sev, were  
509 able to capture the differences in glucose fluctuations due to different meals (Fig. S12A).<sup>19</sup>  
510 By contrast, one-way analysis of variance for testing the significance of differences in  
511 AC\_Mean and AC\_Var for each meal showed no significant difference (Fig. S12B),  
512 suggesting that AC\_Mean and AC\_Var were more robust to meal types.

513

### 514 **AC\_Mean and AC\_Var capture changes in blood glucose dynamics in the early stage of** 515 **glucose intolerance**

516 To further validate the predictive characteristics of AC\_Mean and AC\_Var in identifying  
517 reduced blood glucose control ability, we characterized them using simulated blood glucose  
518 data. We previously reported that as DI decreases, insulin clearance decreases simultaneously  
519 in the early stage of glucose intolerance.<sup>28</sup> Hence, we evaluated how AC\_Mean and AC\_Var  
520 change as DI and insulin clearance decrease simultaneously.

521 For simulation of the mathematical model (see Methods), we used parameters  
522 reported as the mean values in NGT.<sup>30</sup> We changed DI ( $k_{sec}k_{sen}$ ) and insulin clearance ( $k_{cle}$ )  
523 from one-half to twice the NGT's values (Fig. 6A). As  $k_{sec}k_{sen}$  and  $k_{cle}$  increased, FBG  
524 levels remained unchanged (Fig. 6A, # $\alpha$ ), but there was a point at which blood glucose levels  
525 decreased (Fig. 6A, # $\beta$ ) and a point at which blood glucose levels increased (Fig. 6A, # $\gamma$ ). As  
526 the pattern of blood glucose dynamics changed in this way, AC\_Mean increased and AC\_Var  
527 decreased (Fig. 6B), consistent with the results that AC\_Mean was positively correlated with

528 insulin clearance, and AC\_Var was negatively correlated with DI and insulin clearance (Fig.  
529 2A).

530 We also investigated the effects of noise on AC\_Mean and AC\_Var (Supplementary  
531 text 3, Figs. 6C, S13 and S14), and found that AC\_Var was more robust to noise than  
532 AC\_Mean, consistent with the result that AC\_Var exhibited a stronger correlation with DI  
533 than AC\_Mean (Fig. 2A). Moreover, extending the measurement period and decreasing the  
534 measurement interval of CGM were found to enhance the accuracy of reduced blood glucose  
535 control ability (Supplementary text 3 and Fig. S14).

536

### 537 **Web application for calculating CGM-derived indices**

538 To easily calculate CGM-derived indices, we developed a web application  
539 (<https://cgm-ac-mean-std.streamlit.app/>) that calculates CGM\_Mean, CGM\_Std, AC\_Mean,  
540 and AC\_Var (Fig. S15). This application was implemented in streamlit. In using this  
541 application, glucose should be measured every 5 min. The application can also run on a local  
542 machine using the code in GitHub repository  
543 ([https://github.com/HikaruSugimoto/CGM\\_AC](https://github.com/HikaruSugimoto/CGM_AC)).

544

### 545 **DISCUSSION**

546 In this study, we found that CGM-derived indices, including AC\_Mean and AC\_Var, were  
547 effective in identifying individuals with reduced blood glucose control ability within a  
548 population predominantly consisting of individuals with NGT. AC\_Mean exhibited a  
549 significant correlation with insulin clearance, and AC\_Var was significantly correlated with  
550 both insulin clearance and DI. Insulin clearance predicts the incidence of T2DM in non-DM  
551 subjects,<sup>36</sup> and DI predicts the development of future T2DM beyond FBG and PG120.<sup>37</sup>  
552 Collectively, these findings suggest that CGM-derived indices, including AC\_Mean and  
553 AC\_Var, can identify abnormalities in blood glucose regulation at an early stage, potentially

554 serving as alternatives to single-point blood tests or OGTT, which have been found to be  
555 inadequate<sup>9-11</sup> or inconvenient<sup>12</sup> for the screening of pre-DM.

556 We also predicted DI and glucose dysregulation by using multiple linear regression,  
557 PLS regression, Lasso regression, random forests, and logistic regression with L1  
558 regularization. DI is suggested to be a predictor of T2DM development,<sup>37</sup> and decreases in  
559 insulin sensitivity and insulin secretion reportedly precede the onset of T2DM.<sup>1</sup> However,  
560 accurate measurement of DI, insulin sensitivity, and insulin secretion are laborious. The  
561 prediction models in this study included only indices derived from a single-point blood test,  
562 physical examinations, and CGM, which are relatively easy-to-measure variables. Given that  
563 the accuracy of the linear regression model with CGM\_Std and AC\_Var as input variables  
564 and clamp DI as the objective variable was about the same as the accuracy of predicting  
565 clamp DI from oral DI, these relatively easy-to-measure variables may be alternatives to  
566 OGTT and clamp tests under some conditions. In this study, we investigated two different  
567 datasets, but both datasets were small in size and included only three T2DM subjects (Table  
568 S1). The main purpose of this study was not to create a predictor that can be used in clinical  
569 settings; rather, this exploratory study showed that reduced blood glucose control ability may  
570 be predictable using CGM and that AC\_Mean and AC\_Var can be useful in the prediction.  
571 Larger studies are required for more accurate predictions of the abnormalities.

572 AC\_Mean and AC\_Var exhibited low collinearity with other CGM-derived indices  
573 and showed the potential to capture changes in blood glucose dynamics indicative of  
574 early-stage glucose intolerance (Figs. 2-5). The mathematical modeling further highlighted  
575 their potential in identifying abnormalities even when FBG levels remain unchanged (Fig. 6).  
576 Collectively, these results indicate that AC\_Mean and AC\_Var can capture glycemetic  
577 disability that cannot be captured by the conventional indices. However, the exact underlying  
578 mechanisms of these results and their relationship with other CGM-derived indices remain  
579 unknown. In this study, we investigated only the mean and the variance of the autocorrelation

580 function at lags 1–30, relatively well-known CGM-derived indices,<sup>25</sup> and three indices that  
581 have been reported to identify abnormal glucose regulation.<sup>19</sup> However, the mean and the  
582 variance of the autocorrelation function at lags 1–2 (Fig. S4) were also significantly  
583 correlated with oral DI ( $r = -0.29$ ;  $P = 0.02$  and  $r = 0.29$ ,  $P = 0.02$ , respectively), and other  
584 CGM-derived indices of glycemic variability have been reported.<sup>26,45–56</sup> It is necessary to  
585 investigate these indices comprehensively to determine the extent to which abnormalities can  
586 be identified from CGM in the future.

587 In conclusion, the current study demonstrated that CGM-derived indices, AC\_Mean  
588 and AC\_Var, can detect decreased blood glucose control ability beyond conventional markers  
589 such as FBG, HbA1c, and other CGM-derived indices. Furthermore, the results indicate that  
590 CGM could potentially estimate DI, a strong indicator of glucose dysregulation and T2DM  
591 onset. This suggests that CGM-derived DI (CGM DI) may serve as an alternative to the  
592 labor-intensive measurements involved in conventional DI assessment using OGTT (oral DI)  
593 or clamp tests (clamp DI).

594

## 595 **Acknowledgments**

596 **Personal Thanks.** We thank Mio Shudo and Yuka Nakamura for their assistance with the  
597 analysis; and our laboratory members for critically reading this manuscript

598 **Author Contributions.** H.S. analyzed the data. H.S., K.H., T.N., T.Y., H.M., N.O-S., M.F.,  
599 Y.H., K.S., W.O., and S.K. wrote the manuscript. T.N., T.Y., H.M, and N.O-S. conducted  
600 clinical examinations. W.O. and S.K. supervised the study.

601 **Data sharing statement.** The CGM data that support the findings of this study are available  
602 from the GitHub repository ([https://github.com/HikaruSugimoto/CGM\\_AC](https://github.com/HikaruSugimoto/CGM_AC)). The code that  
603 calculates AC\_Mean and AC\_Var is also available from the repository  
604 ([https://github.com/HikaruSugimoto/CGM\\_AC](https://github.com/HikaruSugimoto/CGM_AC)) and the web application  
605 (<https://cgm-ac-mean-std.streamlit.app/>).




606 **Conflict of Interest.** The authors have no competing interests to declare.


607 **Funding and Assistance.** This study was supported by the Japan Society for the Promotion  
608 of Science (JSPS) KAKENHI (JP21H04759), CREST, the Japan Science and Technology  
609 Agency (JST) (JPMJCR2123), and The Uehara Memorial Foundation.

610 **Figure Legends**

**Subject #13**




**Subject #46**



611

612 **Fig. 1. Blood glucose fluctuations and correlogram of the time series data.** Time courses  
613 of blood glucose levels measured by continuous glucose monitoring in two subjects and their  
614 correlograms. Red lines indicate the mean value of the autocorrelation function (AC\_Mean),

615 and red shaded areas indicate the variance value of the autocorrelation function (AC\_Var)  
616 (see Methods). Lag 1 autocorrelation of blood glucose measurements taken at 5-min intervals  
617 refers to the relationship between the current value (Blood glucose [t]) and the value recorded  
618 one time point later (Blood glucose [t+5x1]). Lag 5 and lag 15 similarly refers to the  
619 relationship between the current value (blood glucose [t]) and the value recorded five time  
620 points later (blood glucose [t+5x5]) and 15 time points later (blood glucose [t+5x15]),  
621 respectively.  
622




623

624 **Fig. 2. Correlation between the indices from CGM and those from OGTT or clamp tests.**


625 (A) Heatmap of Spearman's correlation coefficient, with the  $P$  values corresponding to

626 testing the hypothesis of no correlation. CGM\_Mean and CGM\_Std indicate the mean value  
627 and standard deviation of blood glucose levels measured by CGM, respectively. DTW\_Low,  
628 DTW\_Mod, and DTW\_Sev are previously reported indices of glucose variability and glucose  
629 dysregulation<sup>19</sup> (see Methods). AC\_Mean and AC\_Var are the mean and the variance value  
630 of the autocorrelation function of blood glucose fluctuations measured by CGM, respectively.  
631 The parameters  $k_4$ ,  $k_5$ , and  $k_7$  correspond to insulin sensitivity, insulin secretion, and  
632 insulin clearance, respectively. (B) Scatter plots for DTW\_Sev versus AC\_Var. Subjects were  
633 colored based on diabetes diagnosis (the left) and the value of clamp DI (the right). This  
634 diagnosis is based on the American Diabetes Association Guidelines of HbA1c, fasting blood  
635 glucose, and OGTT. An NGT subject who had high AC\_Var and high DTW\_Sev had low  
636 clamp DI (\*1). Some subjects had low DTW\_Sev and low clamp DI (\*2), and others had low  
637 AC\_Var and low clamp DI (\*3). (C) Hierarchical clustering analysis of the standardized  
638 CGM-derived indices using Euclidean distance as a metric with the Ward method. The  
639 columns represent the standardized value of DTW\_Mod, DTW\_Sev, and AC\_Var. The rows  
640 represent individual subjects. The subjects are grouped and sorted according to their degree  
641 of relatedness. (D) Box plots of the value of oral DI and clamp DI for each cluster. Blue, red,  
642 green, and magenta are related to clusters 1, 2, 3, and 4, respectively. The boxes denote the  
643 median and upper and lower quartiles. Each point corresponds to the value for a single  
644 subject. \* $P < 0.05$ . Abbreviations: AUC\_IRI, area under insulin curve during the first 10 min  
645 of hyperglycemic clamp test; CGM, continuous glucose monitoring; DI, disposition index;  
646 I.I., insulinogenic index; ISI, insulin sensitivity index; NGT, normal glucose tolerance;  
647 OGTT, oral glucose tolerance test; PG120, plasma glucose concentration at 120 min during  
648 the OGTT.

649



651 **Fig. 3. Multivariate analyses for predicting the DI.** (A) VIF of all variables. (B) VIF of  
652 each variable remaining after removing the variable with the highest VIF one by one until the  
653 VIF of all variables are less than 10. (C) VIP generated from the PLS regression predicting  
654 oral DI. Variables with a  $VIP \geq 1$  (the dotted line) were considered to be significantly  
655 contributed to the prediction. (D) VIP generated from the PLS regression predicting clamp DI.  
656 Abbreviations: ACir, abdomen circumference; BMI, body mass index; DBP, diastolic blood  
657 pressure; DI, disposition index; FBG, fasting blood glucose; HDL-C, high-density lipoprotein  
658 cholesterol; LDL-C, low-density lipoprotein cholesterol; PLS: partial least squares; SBP,  
659 systolic blood pressure; TC, total cholesterol; TG, triglycerides; VIF, variance inflation  
660 factor; VIP, variable importance in projection.  
661



662

663

664

665

666

667

668

669

670

671

672

673

674

**Fig. 4. Correlation network of clinical parameters.** A spring layout of the correlation network of 17 CGM-derived indices; 3 blood glucose level-related indices; 9 insulin sensitivity, secretion, and clearance-related indices; and 9 other lifestyle diseases-related indices obtained from a single blood test or physical measurement. Relationship with the absolute values of the Spearman's correlation coefficient of 0.25 or higher are connected with edges. The width of the edges is proportional to the corresponding correlation coefficient. The color of the nodes indicates the type of indices: red, magenta, blue, green is associated with CGM, blood glucose levels, insulin, and other lifestyle-related diseases, respectively. Abbreviations: ACir, abdomen circumference; BMI, body mass index; CGM: continuous glucose monitoring; DBP, diastolic blood pressure; DI, disposition index; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; I.I., insulinogenic index; ISI, insulin sensitivity index; LDL-C, low-density lipoprotein cholesterol; oral AUC\_IRI, area under



675 insulin curve during the first 10 min of hyperglycemic clamp test; PG120, plasma glucose  
676 concentration at 120 min during the oral glucose tolerance test; SBP, systolic blood pressure;  
677 TC, total cholesterol; TGs, triglycerides. The parameters  $k_4$ ,  $k_5$ , and  $k_7$  correspond to  
678 insulin sensitivity, insulin secretion, and insulin clearance, respectively.


679

680



685 VIF one by one until the VIF of all variables are less than 10. (C) Scatter plot for the VIF of  
686 the indices calculated using the previously reported dataset (VIFp) versus those calculated  
687 using the dataset obtained in this study (VIFt). Each point corresponds to the values for an  
688 index.  $r$  is Spearman's correlation coefficient and the  $P$  value is for testing the hypothesis  
689 of no correlation. (D) VIP generated from the PLS regression predicting SSPG. Variables  
690 with a  $VIP \geq 1$  (the dotted line) were considered to be significantly contributed to the  
691 prediction. (E) A spring layout the of correlation network of 17 CGM-derived indices, 3  
692 blood glucose levels-related indices, 1 insulin sensitivity-related index, 5 other lifestyle  
693 diseases-related indices obtained from a single blood test or physical measurement.  
694 Relationships with the absolute values of the Spearman's correlation coefficient of 0.25 or  
695 higher are connected with edges. The width of the edges is proportional to the corresponding  
696 correlation coefficient. The color of the nodes indicates the type of indices: red, magenta,  
697 blue, green is associated with CGM, blood glucose levels, insulin, and other lifestyle-related  
698 diseases, respectively. Abbreviations: BMI, body mass index; CGM, continuous glucose  
699 monitoring; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol;  
700 LDL-C, low-density lipoprotein cholesterol; PLS: partial least squares; SSPG, steady state  
701 plasma glucose; TC, total cholesterol; TGs, triglycerides; VIF, variance inflation factor; VIP,  
702 variable importance in projection.

703



704

705 **Fig. 6. Characterization of AC\_Mean and AC\_Var using simulated blood glucose. (A)**

706 24-h simulated glucose concentration. The color of the line is based on the values of

707  $k_{sec}k_{sen}$  and  $k_{cle}$ . The enlarged views of the areas are shown in # $\alpha$ -# $\gamma$ . (B) The relationship  
708 between  $k_{sec}k_{sen}$ ,  $k_{cle}$  and AC\_Mean (the left). That of AC\_Var is shown in the right. The  
709 horizontal axis represents the ratio of  $k_{sec}k_{sen}$  and  $k_{cle}$  to the reported average values for  
710 healthy subjects. (C) AC\_Mean (the upper panels) and AC\_Var (the lower panels) simulated  
711 from the glucose concentration with gaussian white noise. AC\_Mean and AC\_Var calculated  
712 in each trial are shown in the left panels. The distributions of AC\_Mean and AC\_Var are  
713 shown in the right. The blue is simulated using the parameters reported as the average values  
714 for healthy subjects. The green is simulated at half the average values. The  $P$  values are for  
715 testing the hypothesis of no difference between the two groups.

716

717 **Table 1.** Multiple regression analyses with oral DI index or clamp DI. (A) Multiple  
718 regression analysis between oral DI and CGM-derived indices, DTW\_Mod, DTW\_Sev, and  
719 AC\_Var.

	Coefficient	SE	<i>P</i>	95% CI
DTW_Mod	0.029	0.17	0.87	-0.31 - 0.37
DTW_Sev	-0.22	0.17	0.20	-0.56 - 0.12
AC_Var	-0.16	0.071	0.029*	-0.3 - -0.017

721 (B) Multiple regression analysis between clamp DI and CGM-derived indices, DTW\_Mod,  
722 DTW\_Sev, and AC\_Var.

	Coefficient	SE	<i>P</i>	95% CI
DTW_Mod	7.7	7.1	0.28	-6.4 - 22
DTW_Sev	4.6	7.1	0.52	-9.6 - 19
AC_Var	-7.8	2.9	0.010*	-14 - -1.9

724 (C) Multiple regression analysis between clamp DI and CGM-derived indices, CGM\_Std and  
725 AC\_Var. \**P* < 0.05

	Coefficient	SE	<i>P</i>	95% CI
CGM_Std	-6.5	3.0	0.035*	-12.5 - -0.48
AC_Var	-6.1	3.0	0.048*	-12 - -0.05

727 DI, disposition index; CGM, continuous glucose monitoring.

728 **References**

- 729 1 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk  
730 state for diabetes development. *Lancet* 2012; **379**: 2279–90.
- 731 2 Heianza Y, Hara S, Arase Y, *et al.* HbA1c 5· 7–6· 4% and impaired fasting plasma  
732 glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan  
733 (TOPICS 3): a longitudinal cohort study. *Lancet* 2011; **378**: 147–55.
- 734 3 Nathan DM, Davidson MB, DeFronzo RA, *et al.* Impaired fasting glucose and impaired  
735 glucose tolerance: implications for care. *Diabetes Care* 2007; **30**: 753–9.
- 736 4 Plantinga LC, Crews DC, Coresh J, *et al.* Prevalence of chronic kidney disease in US  
737 adults with undiagnosed diabetes or prediabetes. *Clin J Am Soc Nephrol* 2010; **5**: 673–  
738 82.
- 739 5 Barr ELM, Zimmet PZ, Welborn TA, *et al.* Risk of cardiovascular and all-cause  
740 mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired  
741 glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).  
742 *Circulation* 2007; **116**: 151–7.
- 743 6 Gillies CL, Abrams KR, Lambert PC, *et al.* Pharmacological and lifestyle interventions  
744 to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic  
745 review and meta-analysis. *BMJ* 2007; **334**: 299.
- 746 7 Alberti KGMM. Screening and diagnosis of prediabetes: where are we headed? *Diabetes*  
747 *Obes Metab* 2007; **9**: 12–6.
- 748 8 Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug  
749 and lifestyle intervention following opportunistic screening for pre-diabetes in primary  
750 care. *Diabetologia* 2010; **53**: 875–81.
- 751 9 Kermod-Scott B. Fasting plasma glucose is inadequate screening test for prediabetes in  
752 obese youth. *BMJ* 2008; **337**: a488.
- 753 10 Sumner AE, Thoreson CK, O'Connor MY, *et al.* Detection of abnormal glucose  
754 tolerance in Africans is improved by combining A1C with fasting glucose: the Africans  
755 in America Study. *Diabetes Care* 2015; **38**: 213–9.
- 756 11 Sumner AE, Duong MT, Aldana PC, *et al.* A1C Combined With Glycated Albumin  
757 Improves Detection of Prediabetes in Africans: The Africans in America Study.  
758 *Diabetes Care* 2016; **39**: 271–7.
- 759 12 Sacks DB. A1C versus glucose testing: a comparison. *Diabetes Care* 2011; **34**: 518–23.
- 760 13 Suh S, Kim JH. Glycemic variability: How do we measure it and why is it important?  
761 *Diabetes Metab J* 2015; **39**: 273–82.
- 762 14 Tang X, Li S, Wang Y, *et al.* Glycemic variability evaluated by continuous glucose  
763 monitoring system is associated with the 10-y cardiovascular risk of diabetic patients  
764 with well-controlled HbA1c. *Clin Chim Acta* 2016; **461**: 146–50.

- 765 15 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying  
766 insulin secretion and resistance. *Am J Physiol* 1979; **237**: E214-23.
- 767 16 Rizos EC, Kannelopoulou A, Filis P, *et al.* Difference on Glucose Profile From  
768 Continuous Glucose Monitoring in People With Prediabetes vs. Normoglycemic  
769 Individuals: A Matched-Pair Analysis. *J Diabetes Sci Technol* 2022; :  
770 19322968221123530.
- 771 17 Hanefeld M, Sulk S, Helbig M, Thomas A, Köhler C. Differences in Glycemic  
772 Variability Between Normoglycemic and Prediabetic Subjects. *J Diabetes Sci Technol*  
773 2014; **8**: 286–90.
- 774 18 Keshet A, Shilo S, Godneva A, *et al.* CGMap: Characterizing continuous glucose  
775 monitor data in thousands of non-diabetic individuals. *Cell Metab* 2023; **35**: 758-769.e3.
- 776 19 Hall H, Perelman D, Breschi A, *et al.* Glucotypes reveal new patterns of glucose  
777 dysregulation. *PLoS Biol* 2018; **16**: e2005143.
- 778 20 Marco A, Pazos-Couselo M, Moreno-Fernandez J, *et al.* Time above range for  
779 predicting the development of type 2 diabetes. *Front Public Health* 2022; **10**: 1005513.
- 780 21 Miya A, Nakamura A, Handa T, *et al.* Log-linear relationship between endogenous  
781 insulin secretion and glycemic variability in patients with type 2 diabetes on continuous  
782 glucose monitoring. *Sci Rep* 2021; **11**: 9057.
- 783 22 Jin S-M, Kim T-H, Bae JC, *et al.* Clinical factors associated with absolute and relative  
784 measures of glycemic variability determined by continuous glucose monitoring: An  
785 analysis of 480 subjects. *Diabetes Res Clin Pract* 2014; **104**: 266–72.
- 786 23 Chen T, Xu F, Su J-B, *et al.* Glycemic variability in relation to oral disposition index in  
787 the subjects with different stages of glucose tolerance. *Diabetol Metab Syndr* 2013; **5**:  
788 38.
- 789 24 Li C, Ma X, Lu J, *et al.* Decreasing complexity of glucose time series derived from  
790 continuous glucose monitoring is correlated with deteriorating glucose regulation. *Front*  
791 *Med* 2023; **17**:68–74.
- 792 25 Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal  
793 reference range for mean tissue glucose and glycemic variability derived from  
794 continuous glucose monitoring for subjects without diabetes in different ethnic groups.  
795 *Diabetes Technol Ther* 2011; **13**: 921–8.
- 796 26 Kohnert KD, Heinke P, Vogt L, *et al.* Declining  $\beta$ -cell function is associated with the  
797 lack of long-range negative correlation in glucose dynamics and increased glycemic  
798 variability: a retrospective analysis in patients with type 2 diabetes. *Journal of Clinical*  
799 *& Translational Endocrinology* 2014; **1**: 192–9.
- 800 27 Thomas F, Pretty C, Dickson J, Signal M, Shaw G, Chase JG. A Simple Method to  
801 Model a Continuous Glucose Monitoring Signal. *IFAC-PapersOnLine* 2017; **50**: 8775–  
802 80.



- 803 28 Sugimoto H, Hironaka KI, Yamada T, Sakaguchi K, Ogawa W, Kuroda S. DI/cle, a  
804 Measure Consisting of Insulin Sensitivity, Secretion, and Clearance, Captures Diabetic  
805 States. *bioRxiv* 2022: 2022-12.
- 806 29 Ohashi K, Komada H, Uda S, *et al.* Glucose Homeostatic Law: Insulin Clearance  
807 Predicts the Progression of Glucose Intolerance in Humans. *PLoS One* 2015; **10**:  
808 e0143880.
- 809 30 De Gaetano A, Arino O. Mathematical modelling of the intravenous glucose tolerance  
810 test. *J Math Biol* 2000; **40**: 136–68.
- 811 31 Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics.  
812 *Chemometrics Intellig Lab Syst* 2001; **58**: 109–30.
- 813 32 Wei H, Sun J, Shan W, *et al.* Environmental chemical exposure dynamics and machine  
814 learning-based prediction of diabetes mellitus. *Sci Total Environ* 2022; **806**: 150674.
- 815 33 Tibshirani R. Regression shrinkage and selection via the lasso. *J R Stat Soc* 1996; **58**:  
816 267–88.
- 817 34 Breiman L. Random Forests. *Mach Learn* 2001; **45**: 5–32.
- 818 35 Kursa MB, Rudnicki WR. Feature Selection with the Boruta Package. *J Stat Softw* 2010;  
819 **36**: 1–13.
- 820 36 Lee CC, Haffner SM, Wagenknecht LE, *et al.* Insulin clearance and the incidence of  
821 type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. *Diabetes*  
822 *Care* 2013; **36**: 901–7.
- 823 37 Utzschneider KM, Prigeon RL, Faulenbach MV, *et al.* Oral disposition index predicts  
824 the development of future diabetes above and beyond fasting and 2-h glucose levels.  
825 *Diabetes Care* 2009; **32**: 335–41.
- 826 38 Lorenzo C, Wagenknecht LE, Rewers MJ, *et al.* Disposition index, glucose effectiveness,  
827 and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).  
828 *Diabetes Care* 2010; **33**: 2098–103.
- 829 39 Gong Z, Chen H. Sequential data classification by dynamic state warping. *Knowl Inf*  
830 *Syst* 2018; **57**: 545–70.
- 831 40 Hulman A, Foreman YD, Brouwers MCGJ, *et al.* Towards precision medicine in  
832 diabetes? A critical review of glucotypes. *PLoS Biol* 2021; **19**: e3000890.
- 833 41 Breschi A, Perelman D, Snyder MP. Response to Hulman and colleagues regarding  
834 “Glucotypes reveal new patterns of glucose dysregulation.” *PLoS Biol* 2021; **19**:  
835 e3001092.
- 836 42 Pei X, Qi D, Liu J, *et al.* Screening marker genes of type 2 diabetes mellitus in mouse  
837 lacrimal gland by LASSO regression. *Sci Rep* 2023; **13**: 6862.
- 838 43 Wang C, Kong H, Guan Y, *et al.* Plasma phospholipid metabolic profiling and  
839 biomarkers of type 2 diabetes mellitus based on high-performance liquid

- 840 chromatography/electrospray mass spectrometry and multivariate statistical analysis.  
841 *Anal Chem* 2005; **77**: 4108–16.
- 842 44 Huang T, Glass K, Zeleznik OA, *et al.* A Network Analysis of Biomarkers for Type 2  
843 Diabetes. *Diabetes* 2019; **68**: 281–90.
- 844 45 Matabuena M, Petersen A, Vidal JC, Gude F. Glucodensities: A new representation of  
845 glucose profiles using distributional data analysis. *Stat Methods Med Res* 2021; **30**:  
846 1445–64.
- 847 46 Costa MD, Henriques T, Munshi MN, Segal AR, Goldberger AL. Dynamical  
848 glucometry: use of multiscale entropy analysis in diabetes. *Chaos* 2014; **24**: 033139.
- 849 47 Yamamoto N, Kubo Y, Ishizawa K, *et al.* Detrended fluctuation analysis is considered  
850 to be useful as a new indicator for short-term glucose complexity. *Diabetes Technol  
851 Ther* 2010; **12**: 775–83.
- 852 48 Ogata H, Tokuyama K, Nagasaka S, *et al.* Long-range negative correlation of glucose  
853 dynamics in humans and its breakdown in diabetes mellitus. *Am J Physiol Regul Integr  
854 Comp Physiol* 2006; **291**: R1638-43.
- 855 49 Thomas F, Signal M, Chase JG. Using Continuous Glucose Monitoring Data and  
856 Detrended Fluctuation Analysis to Determine Patient Condition: A Review. *J Diabetes  
857 Sci Technol* 2015; **9**: 1327–35.
- 858 50 Klaus-Dieter K, Heinke P, Vogt L, *et al.* Indices for assessment of the quality of  
859 glycemic control and glucose dynamics from continuous glucose monitoring. *Int J  
860 Diabetes Clin Res* 2017; **4**: 071.
- 861 51 Crenier L. Poincaré plot quantification for assessing glucose variability from continuous  
862 glucose monitoring systems and a new risk marker for hypoglycemia: application to  
863 type 1 diabetes patients switching to continuous subcutaneous insulin infusion. *Diabetes  
864 Technol Ther* 2014; **16**: 247–54.
- 865 52 Rodríguez de Castro C, Vigil L, Vargas B, *et al.* Glucose time series complexity as a  
866 predictor of type 2 diabetes. *Diabetes Metab Res Rev* 2017; **33**. DOI:10.1002/dmrr.2831.
- 867 53 Peyser TA, Balo AK, Buckingham BA, Hirsch IB, Garcia A. Glycemic Variability  
868 Percentage: A Novel Method for Assessing Glycemic Variability from Continuous  
869 Glucose Monitor Data. *Diabetes Technol Ther* 2018; **20**: 6–16.
- 870 54 Raubertas R, Beech J, Watson W, *et al.* Decreased complexity of glucose dynamics in  
871 diabetes in rhesus monkeys. *Sci Rep* 2019; **9**: 1438.
- 872 55 Whitelaw BC, Choudhary P, Hopkins D. Evaluating rate of change as an index of  
873 glycemic variability, using continuous glucose monitoring data. *Diabetes Technol Ther  
874* 2011; **13**: 631–6.
- 875 56 Rodbard D. Glucose Variability: A Review of Clinical Applications and Research  
876 Developments. *Diabetes Technol Ther* 2018; **20**: S25–215.
- 877